NRAS and melanoma: In the group of ipilimumab plus nivolumab, mPFS was significantly higher for melanoma with BRAF mutation (9.9 months; 95% CI, 6.8–17.2 months) compared with NRAS‐mutant (4.8 months; 95% CI, 3.0–7.5 months) and BRAF/NRAS wild‐type (5.3 months; 95% CI, 3.6–7.1 months) [413].